A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)

Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups

“…Objective response rate (ORR) and tolerability were also remarkably better than Gemcitabine + Carboplatin. Results from study EURTAC (MILLER et al, 2009;Inal et al, 2012). suggested median PFSs were 9.7 and 5.2 months, respectively, with Erlotinib and standard first-line therapy for in western NSCLC patients with EGFR sensitive mutations.…”

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

“…The preliminary results of some of these studies suggest that this mAb, used in combination with the TKI erlotinib, produces a clear benefit in term of PFS and probably, also in terms of OS. 19 In this contest, even though bevacizumab addition to chemotherapy appears to produce benefit in the treatment of advanced NSCLC, it is also clear that the most active combination and the optimal administration strategy have not been identified yet.…”

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Versus Placebo as Maintenance Therapy for Advanced Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

“…Sequentially, through full-text review, 59 more non-RCT articles, articles on the same topic or the articles failed to meet inclusion criteria were excluded. Furthermore, other excluded literatures were: one study covered the patients with Stage IIIA NSCLC (Kelly et al, 2008); one study (Miller et al, 2009) had the patients been treated with combined monoclonal antibody (bevacizumab) and placebo in the control group; one study (Takeda et al, 2010) had the patients been treated with platinum-based maintenance therapy as the controls and a study (Pérol et al, 2012) had the controls only received disease progression observation. As a result, only six studies (Herbst et al, 2005;Gatzemeier et al, 2007;Mok et al, 2009;Cappuzzo et al, 2010;Gaafar et al, 2011;Zhang et al, 2012) were included in the present study eventually (Figure 1).…”